Literature DB >> 22093586

Current therapeutic strategies in adult acute lymphoblastic leukemia.

Adele K Fielding1.   

Abstract

Approximately half of all adults with acute lymphoblastic leukemia now survive long term. This article summarizes the current approaches to treating acute lymphoblastic leukemia in adults, with a focus on a pragmatic approach to decision making. Coupled with a particularly punishing and often complex combination chemotherapy treatment regimen, treatment-related morbidity and mortality are frequent, and this article focuses on these situations. The field will change significantly over the next few years with many ongoing clinical studies and molecular insights which will be translated into providing prognostic information and novel therapeutic targets.
Copyright © 2011 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2011        PMID: 22093586     DOI: 10.1016/j.hoc.2011.09.008

Source DB:  PubMed          Journal:  Hematol Oncol Clin North Am        ISSN: 0889-8588            Impact factor:   3.722


  7 in total

1.  Recognition of adult and pediatric acute lymphoblastic leukemia blasts by natural killer cells.

Authors:  Giovanni F Torelli; Nadia Peragine; Sara Raponi; Daria Pagliara; Maria S De Propris; Antonella Vitale; Alice Bertaina; Walter Barberi; Lorenzo Moretta; Giuseppe Basso; Angela Santoni; Anna Guarini; Franco Locatelli; Robin Foà
Journal:  Haematologica       Date:  2014-03-21       Impact factor: 9.941

2.  Outcome of patients with acute lymphoblastic leukemia (ALL) following induction therapy with a modified (pulsed dexamethasone rather than continuous prednisone) UKALL XII/ECOG E2993 protocol at Tawam Hospital, United Arab Emirates (UAE).

Authors:  Inaam B Hassan; Jorgen Kristensen; Hussain Alizadeh; Roos Bernsen
Journal:  Med Oncol       Date:  2013-03-07       Impact factor: 3.064

Review 3.  Advances in biology of acute lymphoblastic leukemia (ALL) and therapeutic implications.

Authors:  Mahsa Mohseni; Hasan Uludag; Joseph M Brandwein
Journal:  Am J Blood Res       Date:  2018-12-10

Review 4.  Treatment of Relapsed/Refractory Acute Lymphoblastic Leukemia in Adults.

Authors:  Aharon Ronson; Ariella Tvito; Jacob M Rowe
Journal:  Curr Oncol Rep       Date:  2016-06       Impact factor: 5.075

5.  Serum neuron-specific enolase levels are upregulated in patients with acute lymphoblastic leukemia and are predictive of prognosis.

Authors:  Cheng-Cheng Liu; Hua Wang; Jing-Hua Wang; Liang Wang; Qi-Rong Geng; Xiao-Qin Chen; Yue Lu
Journal:  Oncotarget       Date:  2016-08-23

6.  Targeting WEE1 to enhance conventional therapies for acute lymphoblastic leukemia.

Authors:  Andrea Ghelli Luserna Di Rorà; Neil Beeharry; Enrica Imbrogno; Anna Ferrari; Valentina Robustelli; Simona Righi; Elena Sabattini; Maria Vittoria Verga Falzacappa; Chiara Ronchini; Nicoletta Testoni; Carmen Baldazzi; Cristina Papayannidis; Maria Chiara Abbenante; Giovanni Marconi; Stefania Paolini; Sarah Parisi; Chiara Sartor; Maria Chiara Fontana; Serena De Matteis; Ilaria Iacobucci; Pier Giuseppe Pelicci; Michele Cavo; Timothy J Yen; Giovanni Martinelli
Journal:  J Hematol Oncol       Date:  2018-08-01       Impact factor: 17.388

7.  In vitro and in vivo single-agent efficacy of checkpoint kinase inhibition in acute lymphoblastic leukemia.

Authors:  Ilaria Iacobucci; Andrea Ghelli Luserna Di Rorà; Maria Vittoria Verga Falzacappa; Claudio Agostinelli; Enrico Derenzini; Anna Ferrari; Cristina Papayannidis; Annalisa Lonetti; Simona Righi; Enrica Imbrogno; Silvia Pomella; Claudia Venturi; Viviana Guadagnuolo; Federica Cattina; Emanuela Ottaviani; Maria Chiara Abbenante; Antonella Vitale; Loredana Elia; Domenico Russo; Pier Luigi Zinzani; Stefano Pileri; Pier Giuseppe Pelicci; Giovanni Martinelli
Journal:  J Hematol Oncol       Date:  2015-11-05       Impact factor: 17.388

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.